glp 1 and the brain gut-brain axis for the actions of glucagon-like peptide-1. After a GLP-1 for Weight Loss and
Description
Yes, both mazdutide and tirzepatide are approved for weight management in individuals with obesity or overweight with comorbidities, regardless of diabetes status
Disruptions in homeostasis from quick weight reduction can elevate cortisol and norepinephrine levels, heightening the risk for, or exacerbation of STB
The adverse events that led to discontinuation of therapy were 4.3%, 7.1%, and 6.2% for 5, 10, and 15 mg of tirzepatide, respectively, and 2.6% in the placebo-treated group [30]
Some GLP-1 medications are taken as weekly injections, such as Ozempic, Wegovy, Trulicity, Bydureon, and Zepbound
Funding This publication was supported by the National Laboratory of Translational Neuroscience, RRF-2.3.1-21-2022-00011
10.3390/microorganisms11112651 22 BoyceB
